Another recent study exploring the activity of dacomitinib in patients with EGFR mutant NSCLC with BMs included one patient with G719A and I706T co-mutations; the patient had a CNS response and an overall partial response (PR) to the treatment [102]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.